Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage… EP News Bureau Oct 30, 2025 Phase IIa data show faster infection resolution and shorter hospital stays when AP-SA02 is added to standard antibiotic therapy,…
Antibacterial Resistance Leadership Group (ARLG) begins clinical trial of phage therapy for cystic… EP News Bureau Oct 6, 2022 The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the…
